石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

休市中 07-05 16:08:07

4.340

+0.080

+1.88%

最高4.400	最低4.250	成交量199.80万
今开4.340	昨收4.260	日振幅3.52%
总市值128.86亿	流通市值128.86亿	总股本29.69亿
成交额866.45万	换手率0.07%	流通股本29.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":4.34,"timestamp":1720166887013,"preClose":4.26,"halted":0,"volume":1998000,"delay":0,"floatShares":2969043385,"shares":2969043385,"eps":0.44407,"marketStatus":"休市中","marketStatusCode":7,"change":0.08,"latestTime":"07-05 16:08:07","open":4.34,"high":4.4,"low":4.25,"amount":8664520,"amplitude":0.035211,"askPrice":4.35,"askSize":54000,"bidPrice":4.33,"bidSize":32000,"shortable":3,"etf":0,"ttmEps":0.442599,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"listingDate":1135008000000,"adjPreClose":4.26,"dividendRate":0.039171,"openAndCloseTimeList":[[1720143000000,1720152000000],[1720155600000,1720166400000]],"volumeRatio":0.9432893319823742,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2449251698","title":"石四药集团(02005)已取得卡左双多巴缓释片及达格列净片的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2449251698","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449251698?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:29","pubTimestamp":1720171759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药品监督管理局有关卡左双多巴缓释片及达格列净片 的药品生产注册批件，均属于化学药品第4类，视同通过一致性评价，其中卡左双多巴缓释片是国内企业首家获批。达格列净片主要用于2型糖尿病成人患者及心力衰竭成人患者。诚如本公司日期为2024年3月25日的公告所载，集团的达格列净原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005"],"gpt_icon":0},{"id":"2449251173","title":"石四药(02005.HK)两药获生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2449251173","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449251173?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:27","pubTimestamp":1720171620,"startTime":"0","endTime":"0","summary":"石四药(02005.HK) 公布，已取得国家药监局有关卡左双多巴缓释片及达格列净片的药品生产注册批件，均属于化学药品第4类，视同通过一致性评价，其中卡左双多巴缓释片是国内企业首家获批。卡左双多巴缓释片主要用于治疗原发性帕金森氏病、脑炎后帕金森氏综合症、症状性帕金森氏综合症，及用于对以前用过左旋多巴/脱羧酶抑制剂复方制剂或单用左旋多巴治疗有剂末恶化或运动障碍现象的患者。达格列净片主要用于2型糖尿病成人患者及心力衰竭成人患者。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-05 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230207105255269_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230207105255269_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1361707/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2446541165","title":"港股公告掘金 | 石四药集团：甲磺酸倍他司汀获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2446541165","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446541165?lang=zh_cn&edition=full","pubTime":"2024-06-27 23:12","pubTimestamp":1719501125,"startTime":"0","endTime":"0","summary":"赤子城科技(09911)拟进一步增持NBT Social Networking股份以达到全资控股……","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20190129/20190129153945_60530.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20190129/20190129153945_60530.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02005","YANG","07226","HSTECH","BK1191","HSCEI"],"gpt_icon":0},{"id":"2446589965","title":"石四药(02005.HK)两款原料药获准内地上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446589965","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446589965?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:34","pubTimestamp":1719480840,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK) 公布，旗下甲磺酸倍他司汀已获中国国家药品监督管理局批准，登记成为在上市制剂使用的原料药。据悉，相关药物主要用于治疗梅尼埃病、梅尼埃综合症及眩晕症等疾病伴发的眩晕和头晕感。另外，集团旗下另一款药物肾上腺素亦已获国家药监局批准，登记成为在上市制剂使用的原料药。据了解，相关药物主要用于心脏骤停和过敏性休克的抢救，也可用于其他过敏性疾病的治疗，亦可与局部麻醉药合用而有利局部止血和延长药效。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-27 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1359779&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2445146790","title":"石四药集团麻醉原料药依托咪酯获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2445146790","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445146790?lang=zh_cn&edition=full","pubTime":"2024-06-24 13:15","pubTimestamp":1719206124,"startTime":"0","endTime":"0","summary":"新京报讯（记者张兆慧）6月24日，石四药集团发布公告称，集团的依托咪酯原料药获批上市。依托咪酯主要用作麻醉药，在国内被列入受管制的第二类精神药品目录。目前，石四药集团已持有国内精神药品生产许可证并符合相关的生产管理规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406243111704553.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406243111704553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02005"],"gpt_icon":0},{"id":"2445064796","title":"智通港股早知道 | 中欧就电动汽车反补贴调查启动磋商 人形机器人“夸父”现身华为开发者大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2445064796","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445064796?lang=zh_cn&edition=full","pubTime":"2024-06-24 06:57","pubTimestamp":1719183442,"startTime":"0","endTime":"0","summary":"中欧商定就欧盟对华电动汽车反补贴调查案启动磋商商务部部长王文涛22日应约与欧盟委员会执行副主席兼贸易委员东布罗夫斯基斯举行视频会谈。双方商定，就欧盟对华电动汽车反补贴调查案启动磋商。对此中方坚决反对，将采取一切必要措施，坚定捍卫中国企业的合法权益。纳斯达克金龙中国指数初步收跌0.9%。安徽省凤阳县日前出台楼市新政，明确给予退出宅基地奖励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","159526","LU1242518857.USD","LU0039217434.USD","LU1242518931.SGD","LU0516422366.SGD","BK1589","02005","BK1240","BK0061","BK0005","LU0516422952.EUR","BK1528","BK0089","LU0163747925.USD","BK1184","BK0028","03969","BK0073","BK1610","300024","07226","YANG","02378","BK0196","BK0188","80883","03990","BK0259","LU0251144936.SGD","00883","BK1521","LU0979878070.USD","LU0228367735.SGD","BK0130","LU0048597586.USD","BK1179","BK1238","LU0516422440.USD","LU0516423174.USD","LU0516423091.SGD","HSCEI","HSTECH","BK0122","LU1880383366.USD"],"gpt_icon":0},{"id":"2445205283","title":"石四药集团：依托咪酯获批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2445205283","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445205283?lang=zh_cn&edition=full","pubTime":"2024-06-23 23:57","pubTimestamp":1719158266,"startTime":"0","endTime":"0","summary":"石四药集团在港交所公告，依托咪酯已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。依托咪酯主要用作麻醉药，在国内被列入受管制的第二类精神药品目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406233110978781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406233110978781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2445405542","title":"石四药集团(02005.HK)麻醉药依托咪酯获准登记成为原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2445405542","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445405542?lang=zh_cn&edition=full","pubTime":"2024-06-23 21:09","pubTimestamp":1719148140,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK) 公布，集团的依托咪酯已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。依托咪酯主要用作麻醉药，在内地被列入受管制的第二类精神药品目录。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-21 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1358421/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2445037798","title":"石四药集团(02005)：依托咪酯获国家药品监督管理局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2445037798","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445037798?lang=zh_cn&edition=full","pubTime":"2024-06-23 18:51","pubTimestamp":1719139915,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的依托咪酯已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。依托咪酯主要用作麻醉药，在国内被列入受管制的第二类精神药品目录。目前，集团已持有国内精神药品生产许可证并符合相关的生产管理规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2444122695","title":"石四药集团(02005)取得盐酸艾司洛尔氯化钠注射液(100ml)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2444122695","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444122695?lang=zh_cn&edition=full","pubTime":"2024-06-18 12:02","pubTimestamp":1718683357,"startTime":"0","endTime":"0","summary":"石四药集团(02005)公布，集团已取得中国国家药品监督管理局有关盐酸艾司洛尔氯化...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2441479030","title":"石四药集团(02005)：丁苯酞获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2441479030","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441479030?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:39","pubTimestamp":1717753166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的丁苯酞已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。丁苯酞主要用于治疗轻、中度缺血性脑卒中(或称脑中风)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1132790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2441764552","title":"石四药集团(02005)上涨5.34%，报4.93元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441764552","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441764552?lang=zh_cn&edition=full","pubTime":"2024-06-06 15:29","pubTimestamp":1717658958,"startTime":"0","endTime":"0","summary":"6月6日，石四药集团(02005)盘中上涨5.34%，截至15:29，报4.93元/股，成交1394.75万元。石四药集团有限公司主要通过其全资子公司石家庄四药有限公司生产经营以静脉输液为主的广泛类别的药品，是中国静脉输液行业的领先企业之一，也是中国最大的静脉输液产品出口厂家。除了静脉输液产品，公司还兼顾小容量注射剂、口服制剂、中药制剂及生物制剂的研发和生产经营。截至2023年年报，石四药集团营业总收入58.57亿元、净利润11.95亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/06152940927831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2441226766","title":"港股异动 | 石四药集团(02005)尾盘涨超4% 恩他卡朋片(0.2g)通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2441226766","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441226766?lang=zh_cn&edition=full","pubTime":"2024-06-06 15:17","pubTimestamp":1717658235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石四药集团(02005)尾盘涨超4%，截至发稿，涨4.49%，报4.89港元，成交额1207.65万港元。消息面上，石四药集团公布，集团已取得国家药监局有关恩他卡朋片(0.2g)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第三家获批。恩他卡朋片作为左旋多巴的辅助用药，主要用于治疗帕金森病及剂末现象(症状波动)。此外，石四药集团近日公告称，集团已取得中国国家药品监督管理局有关比索洛尔氨氯地平片(5mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第二家获批。比索洛尔氨氯地平片是复方制剂，主要用于作为高血压治疗的替代疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1131930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","YANG","07226","HSTECH","BK1191","HSCEI"],"gpt_icon":0},{"id":"2440340682","title":"石四药集团06月04日主力资金流出39万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2440340682","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440340682?lang=zh_cn&edition=full","pubTime":"2024-06-04 16:15","pubTimestamp":1717488927,"startTime":"0","endTime":"0","summary":"06月04日, 石四药集团股价涨2.15%，报收4.75元，成交金额1555万元，换手率0.11%，振幅4.09%，量比1.28。石四药集团今日主力资金净流出39万元，连续3日净流出，上一交易日主力净流出189万元，今日环比减少79.37%。该股近5个交易日下跌0.42%，主力资金累计净流出175万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出233万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041615429f1820af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406041615429f1820af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02005"],"gpt_icon":0},{"id":"2440451546","title":"石四药集团(02005.HK)恩他卡朋片取得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2440451546","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440451546?lang=zh_cn&edition=full","pubTime":"2024-06-03 16:40","pubTimestamp":1717404000,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK) 公布，已取得国家药监局有关恩他卡朋片(0.2g)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第三间获批。恩他卡朋原料药已获药监局批准登记成为在上市制剂使用的原料药。该药物作为左旋多巴的辅助用药，主要用于治疗帕金森病及剂末现象(症状波动)。(sl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-03 12:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220419120905434_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220419120905434_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1353998&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2440451818","title":"石四药集团(02005)获国家药监局有关恩他卡朋片(0.2g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2440451818","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440451818?lang=zh_cn&edition=full","pubTime":"2024-06-03 16:34","pubTimestamp":1717403665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，该集团已取得中国国家药品监督管理局(“国家药监局”)有关恩他卡朋片(0.2g)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第三家获批。恩他卡朋片作为左旋多巴的辅助用药，主要用于治疗帕金森病及剂末现象(症状波动)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2440093456","title":"石四药集团06月03日遭主力抛售189万元 环比增加339.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440093456","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440093456?lang=zh_cn&edition=full","pubTime":"2024-06-03 16:16","pubTimestamp":1717402614,"startTime":"0","endTime":"0","summary":"06月03日, 石四药集团股价跌1.27%，报收4.65元，成交金额1806万元，换手率0.13%，振幅4.03%，量比1.53。石四药集团今日主力资金净流出189万元，上一交易日主力净流出43万元，今日环比增加339.53%。该股近5个交易日下跌2.51%，主力资金累计净流出184万元；近20日主力资金累计净流出195万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406031617439f148c5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406031617439f148c5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2440381764","title":"石四药集团(02005)已取得比索洛尔氨氯地平片(5mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2440381764","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440381764?lang=zh_cn&edition=full","pubTime":"2024-06-03 12:07","pubTimestamp":1717387672,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关比索洛尔氨氯地平片(5mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第二家获批。比索洛尔氨氯地平片是复方制剂，主要用于作为高血压治疗的替代疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191"],"gpt_icon":0},{"id":"2440438941","title":"石四药集团(02005.HK)：比索洛尔氨氯地平片(5mg)通过一致性评价  主要用于作为高血压治疗的替代疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2440438941","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440438941?lang=zh_cn&edition=full","pubTime":"2024-06-03 12:04","pubTimestamp":1717387490,"startTime":"0","endTime":"0","summary":"格隆汇6月3日丨石四药集团(02005.HK)公告，集团已取得中国国家药品监督管理局有关比索洛尔氨氯地平片(5mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第二家获批。比索洛尔氨氯地平片是复方制剂，主要用于作为高血压治疗的替代疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060312045495888717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060312045495888717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02005","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0284},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.1033},{"period":"6month","weight":-0.1143},{"period":"1year","weight":0.0072},{"period":"ytd","weight":-0.1215}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":-0.0339},{"period":"3month","weight":0.0643},{"period":"6month","weight":0.0765},{"period":"1year","weight":-0.0396},{"period":"ytd","weight":0.0441}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.526316,"avgChangeRate":0.012746},{"month":2,"riseRate":0.578947,"avgChangeRate":0.027337},{"month":3,"riseRate":0.684211,"avgChangeRate":0.091025},{"month":4,"riseRate":0.526316,"avgChangeRate":0.042346},{"month":5,"riseRate":0.421053,"avgChangeRate":0.008785},{"month":6,"riseRate":0.526316,"avgChangeRate":0.074246},{"month":7,"riseRate":0.368421,"avgChangeRate":-0.030155},{"month":8,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.061971},{"month":10,"riseRate":0.444444,"avgChangeRate":0.001133},{"month":11,"riseRate":0.722222,"avgChangeRate":0.099601},{"month":12,"riseRate":0.5,"avgChangeRate":-0.005875}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}